Loading...

Bristol-Myers Squibb Company

BRM.DE•XETRA
Healthcare
Drug Manufacturers - General
€40.13
€-1.13(-2.75%)

Bristol-Myers Squibb Company (BRM.DE) Stock Overview

Explore Bristol-Myers Squibb Company’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 76.7/100

Key Financials

Market Cap81.7B
P/E Ratio17.58
EPS (TTM)$2.27
ROE0.32%
Fundamental Analysis

AI Price Forecasts

1 Week$42.65
1 Month$42.40
3 Months$52.10
1 Year Target$39.36

BRM.DE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company (BRM.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 43.88, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $39.36.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.58 and a market capitalization of 81.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

43.88RSI (14)
-0.41MACD
14.25ADX
Revenue Growth
7.32%
↑ 7.32%
Profit Growth
€2.67
↓ 211.50%
EPS Growth
€2.67
↓ 213.66%
Operating Margin
13.87%
↓ 65.86%
ROE
31.93%
↓ 211.50%
Dividend Yield
0.00%
↑ 4.63%
Analyst Recommendations data is not available for BRM.DEAnalyst Recommendations details for BRM.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

CEO

Christopher S. Boerner

Employees

34,100

Headquarters

430 East 29th Street, Princeton, NY

Founded

1999

Frequently Asked Questions

;